Masayuki Takeda Selected Research

imidazolelactic acid

1/2019

Metabolomics analysis of blood identifies potential biomarkers and possible treatment targets for nocturia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masayuki Takeda Research Topics

Disease

69	Neoplasms (Cancer) 09/2022 - 03/2003
55	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2022 - 03/2010
21	Overactive Urinary Bladder (Overactive Bladder) 03/2022 - 02/2005
16	Disease Progression 09/2021 - 11/2010
13	Lower Urinary Tract Symptoms 01/2020 - 07/2011
10	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2017 - 09/2006
9	Neoplasm Metastasis (Metastasis) 01/2022 - 11/2005
8	Lung Neoplasms (Lung Cancer) 09/2021 - 05/2012
6	Nausea 10/2022 - 02/2016
6	Colorectal Neoplasms (Colorectal Cancer) 09/2022 - 09/2011
6	Breast Neoplasms (Breast Cancer) 01/2022 - 09/2006
6	Nocturia 01/2022 - 05/2013
6	Adenocarcinoma of Lung 01/2019 - 09/2012
5	Carcinoma (Carcinomatosis) 01/2022 - 07/2003
5	Renal Cell Carcinoma (Grawitz Tumor) 01/2019 - 11/2005
4	Vomiting 10/2022 - 02/2016
4	Urinary Incontinence 01/2021 - 11/2016
4	Stomach Neoplasms (Stomach Cancer) 12/2016 - 01/2006
3	Melanoma (Melanoma, Malignant) 01/2021 - 03/2018
3	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2021 - 07/2010
3	Diarrhea 05/2018 - 01/2015
3	Infections 02/2017 - 09/2002
3	Inflammation (Inflammations) 01/2017 - 11/2005
2	Urge Urinary Incontinence (Urge Incontinence) 03/2022 - 05/2003
2	Urethral Stricture 02/2022 - 12/2021
2	Exanthema (Rash) 01/2022 - 04/2015
2	Extramammary Paget Disease (Paget Disease, Extramammary) 01/2022 - 01/2016
2	Malignant Mesothelioma 06/2021 - 11/2019
2	Drug-Related Side Effects and Adverse Reactions 01/2021 - 12/2010
2	Meningeal Carcinomatosis 01/2021 - 01/2017
2	Acute Kidney Injury (Acute Renal Failure) 12/2019 - 01/2010

Drug/Important Bio-Agent (IBA)

32	Tyrosine Kinase InhibitorsIBA 09/2021 - 12/2004
27	ErbB Receptors (EGF Receptor)IBA 01/2021 - 01/2006
15	Gefitinib (Iressa)FDA Link 01/2019 - 12/2004
12	Pharmaceutical PreparationsIBA 08/2021 - 11/2005
12	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 07/2010
11	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2011
10	NivolumabIBA 04/2022 - 12/2016
8	osimertinibIBA 09/2021 - 01/2017
8	AfatinibIBA 09/2019 - 04/2015
7	LigandsIBA 01/2021 - 01/2015
7	Neuregulin-1 (Neuregulin 1)IBA 12/2019 - 09/2011
6	Tadalafil (Cialis)FDA Link 01/2020 - 09/2012
6	Alanine Transaminase (SGPT)IBA 01/2019 - 01/2015
5	mirabegronIBA 03/2022 - 06/2014
5	Monoclonal AntibodiesIBA 06/2021 - 01/2011
5	nintedanibIBA 01/2021 - 01/2015
5	Immune Checkpoint InhibitorsIBA 01/2021 - 12/2016
5	PlatinumIBA 01/2021 - 08/2012
5	Messenger RNA (mRNA)IBA 10/2019 - 04/2006
5	Cetuximab (Erbitux)FDA Link 09/2019 - 09/2011
5	Pemetrexed (MTA)FDA Link 01/2019 - 11/2010
5	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2019 - 01/2015
5	Docetaxel (Taxotere)FDA Link 01/2019 - 08/2012
5	Carboplatin (JM8)FDA LinkGeneric 09/2013 - 07/2003
4	Circulating Tumor DNAIBA 09/2021 - 01/2016
4	SteroidsIBA 01/2021 - 03/2016
4	N- (4- ((5- (hydroxy(phenyl)methyl)pyrrolidin- 2- yl)methyl)phenyl)- 4- oxo- 4,6,7,8- tetrahydropyrrolo(1,2- a)pyrimidine- 6- carboxamideIBA 01/2021 - 01/2018
4	Proteins (Proteins, Gene)FDA Link 12/2019 - 01/2012
4	Connexin 43 (Connexin43)IBA 12/2019 - 01/2016
4	Trastuzumab (Herceptin)FDA Link 01/2019 - 03/2015
4	Anaplastic Lymphoma KinaseIBA 09/2018 - 05/2012
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2017 - 11/2005
4	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2014 - 01/2006
4	Paclitaxel (Taxol)FDA LinkGeneric 06/2013 - 07/2003
3	IpilimumabIBA 04/2022 - 08/2020
3	AcidsIBA 01/2022 - 10/2019
3	human ERBB2 proteinIBA 01/2022 - 03/2015
3	Phosphotransferases (Kinase)IBA 01/2021 - 05/2012
3	CytokinesIBA 01/2020 - 11/2005
3	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 08/2014
3	Muscarinic AntagonistsIBA 01/2019 - 02/2005
3	alectinibIBA 09/2018 - 11/2016
3	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 11/2016 - 05/2012
3	Bevacizumab (Avastin)FDA Link 04/2016 - 08/2012
3	Tamsulosin (Flomax)FDA LinkGeneric 10/2013 - 04/2011
3	Cholinergic Antagonists (Anticholinergics)IBA 10/2013 - 02/2005
2	fosaprepitant FDA Link 10/2022 - 06/2022
2	PolymersIBA 02/2022 - 12/2021
2	Hormones (Hormone)IBA 01/2022 - 01/2018
2	palmidrolIBA 01/2022 - 10/2019
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 02/2020
2	entrectinibIBA 01/2022 - 08/2021
2	DNA (Deoxyribonucleic Acid)IBA 08/2021 - 01/2021
2	Formaldehyde (Formol)FDA Link 01/2021 - 01/2019
2	ParaffinIBA 01/2021 - 01/2019
2	RNA (Ribonucleic Acid)IBA 01/2021 - 04/2006
2	AntibodiesIBA 05/2020 - 01/2012

Therapy/Procedure

44	Therapeutics 01/2022 - 11/2005
24	Drug Therapy (Chemotherapy) 10/2022 - 07/2003
7	Aftercare (After-Treatment) 01/2021 - 01/2015
7	Radiotherapy 01/2019 - 11/2005
6	Nephrectomy 12/2021 - 03/2003
4	Adrenalectomy 06/2022 - 05/2012
4	Immunotherapy 08/2020 - 11/2005
3	Adjuvant Chemotherapy 01/2019 - 05/2012
2	Operative Time 06/2022 - 12/2021
2	Genomic Medicine 02/2021 - 09/2018
2	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 07/2003
2	Precision Medicine 01/2021 - 09/2018